fewer CV outcomes (composite of myocardial infarction, stroke, hospitalization for unstable angina, congestive heart failure or revascularization surgery) with bromocriptine-QR compared to placebo (HR 0.60, 95% CI 0.37-0.96). 5 These findings were reaffirmed in subsequent analyses, one which added CV death to the composite (39% relative risk reduction, P = .0346) and evaluated major adverse CV events (MACE), myocardial infarction, stroke and CV death (52% relative risk reduction, P < .05). [6] [7] [8] Colesevelam is a bile acid sequestrant typically used to decrease low-density lipoprotein and is also FDA-approved for T2DM. When added to metformin or insulin therapy, colesevelam lowers HbA1c by approximately 0.5% compared to placebo (P < .001). 9 Colesevelam showed reduced HbA1c by 0.79% in patients on sulphonylurea monotherapy and 0.42% in patients on sulphonylurea combined with other diabetes treatment (P < .001 compared to placebo). Comment: Other non-diabetes medications demonstrating haemoglobin A1c lowering, including agents for weight loss, depression, anaemia and coronary artery disease, are described in this review article.
What is new and Conclusion:
More research looking into the impact of non-diabetes medications on blood glucose may offer additional diabetes treatment strategies.
K E Y W O R D S
diabetes, hemoglobin A1C, prescription medications resulting in secondary HbA1c reductions. Orlistat and lorcaserin are noteworthy medication therapies that indirectly impact weight loss through their metabolic effects, whereas topiramate and bupropion induce weight loss through off-target mechanisms that are not fully elucidated.
| COMMENT
Approximately 85% of adults who are diagnosed with T2DM are overweight. Studies have shown that weight loss of as little as 5%
can significantly enhance glycaemic control. 12 O'Neil et al. 13 investigated this relationship in a randomized placebo-controlled trial that examined the potential impacts of lorcaserin for weight loss in T2DM. Patients who met inclusion criteria were randomly assigned in a 1:1:1 ratio, stratified by oral use of metformin or sulphonylurea, to receive lorcaserin 10 mg twice daily, lorcaserin 10 mg once each morning and placebo in the evening or placebo twice daily. Weight reduction was evident after 2 weeks and remained significantly greater in the lorcaserin groups than in the placebo group throughout the study. The mean HbA1c and fasting blood glucose were significantly reduced in the lorcaserin groups (−1.1% and −25 mg/dL at week 52, respectively) compared to placebo (−0.5% and −10 mg/dL at week 52, respectively) at all time points of the study. Furthermore, the proportion of patients within each group that achieved a goal
HbA1c ≤ 7% at week 52 was also significantly greater in the lorcaserin groups (52.2%) than placebo (26.3%). This study also found that more patients were able to reduce their overall use of oral antidiabetic medications in the lorcaserin groups as compared to placebo and that fewer patients taking lorcaserin increased the total daily dose of antidiabetic agents. Lorcaserin was however associated with more frequent episodes of non-severe hypoglycaemia.
Orlistat is an additional medication that is used for weight loss that has shown positive effects on glycaemic control. The impact of orlistat on glycaemic control has been studied amongst patients who were clinically overweight or obese, diagnosed with T2DM and treated with metformin, sulphonylureas or insulin. 14 Topiramate is FDA-approved for the treatment of seizure disorder and migraine prophylaxis and has also demonstrated weight loss effects in clinical trials. The impact of topiramate in obese, T2DM
on HbA1c was investigated in a randomized, placebo-controlled study conducted by Rosenstock et al. 15 Patients were being treated with diet and exercise alone or in combination with metformin and were randomized to placebo or topiramate, each group undergoing a 7-week titration phase followed by a 9-week maintenance phase, a 2-week taper and a 2-week period of follow-up. The study also involved a personalized 600 kcal deficit diabetes diet, behavioural modifications and a physical activities programme. Final doses of 175 mg (n = 34), 150 mg (n = 1), 75 mg (n = 3) and 50 mg (n = 1) were utilized for patients. In addition to significant weight loss, HbA1c was reduced from baseline by at least 1.0% in 21% and 35% of patients in placebo and topiramate groups, respectively. Overall, the HbA1c improved from a baseline of 7.4% (placebo) and 7.6% (topiramate) did not improve at study visits, the medications were increased to 2 pills daily. Blood was drawn for measurement of sertraline levels, and pills were counted to monitor for adherence to the study medications. HbA1c levels were significantly reduced for both treatment groups, but the decrease in the sertraline group demonstrated a more than 2-fold decrease as compared to the placebo group (−2.0% ± 2.1 vs −0.9% ± 2.0, respectively, P = .0003). 16 The placebo group reduction in HbA1c was possibly attributed to increased interaction with study coordinators and engagement with questionnaires and assessments (behavioural therapy was not provided to study participants).
Ghaeli et al. 17 Of note, the investigators observed that the fasting blood glucose levels in both treatment groups were not dependent on age and gender. 18 Bupropion has demonstrated reduced HbA1c by about 0.5% (P < .01). This was attributed to effective depression management as patients who did not achieve depression remission did not experience this extent of HbA1c reduction. 13 Although depression management may improve glycaemic control, specific agents such as SSRIs or bupropion may have additional benefits for HbA1c lowering, whereas TCAs may increase blood glucose.
Diabetes is a known CV risk factor, especially when glucose is poorly controlled. Ranolazine is an antianginal medication with cardioprotective properties and lowers HbA1c in a dose-dependent manner. 19 This mechanism is not completely understood, but studies utilizing rat models suggest that ranolazine may promote glucosestimulated insulin secretion. Chisholm et al. investigate the effects of ranolazine on fasting prandial glucose (FPG) and HbA1c in diabetic patients with HbA1c of 6%-10% or FPG < 150 or > 150-400 mg/dL.
Ranolazine was found to significantly reduce HbA1c in patients with diabetes and to reduce newly elevated HbA1c in patients with wellmanaged glycaemic control. 19 The average placebo-corrected reduction in HbA1c at 4 months for patients with and without diabetes was 0.42% (P < .001) and 0.18% (P < .001), respectively.
Considering the involvement of red blood cells in the formation
of HbA1c, it is reasonable to suspect that HbA1c can be falsely reduced by medications that induce erythrocyte haemolysis. These medications reduce erythrocyte lifespan and consequently increase the ratio of newly formed erythrocytes, thus reducing the exposure of haemoglobin carried by erythrocytes to be glycated into HbA1c. 20 Dapsone, ribavirin, sulphonamides and antiretroviral medications have been reported to reduce HbA1c through this mechanism. 16 Anaemia is oftentimes associated with deficiencies in iron and vitamin B12, which consequently increase stores of unconjugated haemoglobin. 20 Goals of therapy involve restoring these disturbances to the normal reference range through the use of iron and vitamin B12 supplementation as well as erythropoietin, which aid in the promotion of new young erythrocytes in the circulation. Any of these treatments for anaemia can induce a "diluting phenomena" of erythrocytes that are glycated into HbA1c, thereby falsely reducing HbA1c (in some cases by 0.5%-1.5%) and potentially influencing a clinician to avoid aggressive diabetes management.
| WHAT IS NE W AND CON CLUS I ON
The following medications have also demonstrated various magnitudes of HbA1c changes and are commonly used in clinical practice. 21 It may be worthwhile for clinicians to utilize evidence-based findings, along with clinical judgement, when using these medications if glucose control is of concern. It is important to note that this list is not all-inclusive, and some listed medications may be more clinically significant than others.
• Aripiprazole 
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